AACR 2026
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.
AACR 2026: Researchers define a mechanism‑driven strategy for targeting p53‑mutant cancers
AACR 2026: Novel approach prevents cancer progression, spares surgery for majority of patients with precancerous oral lesions
AACR 2026: Early myocarditis onset after immunotherapy may predict treatment-related fatality
AACR 2026: Exposure to wildfire smoke may be linked to increased risk of developing several cancers
AACR 2026: Intralesional nivolumab may be effective against precancerous oral lesions
AACR 2026: BCMA-directed CAR T-cell therapy may be effective against high-risk smouldering multiple myeloma
AACR 2026: New platform uses machine learning to predict responses in patients with lung cancer
AACR 2026: A machine learning model that uses DNA methylation patterns may help identify the origin of cancers of unknown primary
AACR 2026: Groundbreaking bowel cancer trial follow-up shows zero relapses
AACR 2026: New KIR-CAR T cell therapy shows promise in multiple solid cancers
AACR 2026: A deep learning pathomics platform may help predict response to immunotherapy in lung cancer patients
AACR 2026:Sleep deprivation disrupts gut microbiota, worsening colorectal cancer outcomes
AACR 2026:Older mice may offer new insight into cancer and ageing
AACR 2026: Phase 1 study explores toxicity reduction in combination of trastuzumab deruxtecan and olaparib in advanced HER2-expressing malignancies
AACR 2026: Sleep deprivation disrupts gut microbiota, worsening colorectal cancer outcomes
mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell activation in melanoma
Screen-detectable cancers account for majority of early-onset cancer cases under age 50
Perioperative anti–PD-L1 therapy improves event-free survival in resectable NSCLC with ctDNA-based risk stratification
Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types
Denikitug shows immune activation and early anti-tumour activity in advanced solid tumour
Zedoresertib plus lunresertib shows promising tumour shrinkage in CCNE1-amplified and FBXW7-mutant cancers
Dual integrin inhibitor plus pembrolizumab shows durable responses in ICI-resistant solid tumours
Oral molecular glue degrader with or without spartalizumab shows immune activation and tumour control in solid tumours
ctDNA positivity predicts poor response and recurrence risk in triple-negative breast cancer
Daraxonrasib plus chemotherapy shows promising first-line activity in RAS-mutant metastatic pancreatic cancer
DLL3 expression in circulating tumour cells predicts response to tarlatamab in small cell lung cancer
ZL-1310 shows promising activity in DLL3-positive neuroendocrine carcinomas
Tumour-selective oncolytic adenovirus LOAd703 with chemo shows immune activation and promising responses in pancreatic cancer
Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in metastatic pancreatic cancer
ctDNA predicts early treatment response in HPV-associated anal cancer
Trastuzumab and tucatinib enable organ preservation in HER2-positive rectal cancer
Rilvegostomig clears ctDNA and delays recurrence in high-risk head and neck cancer